New Insight of PSA Reduction During Finasteride Therapy

This document contains summaries of three different studies related to benign prostatic hyperplasia (BPH). The first study evaluated the effect of finasteride on PSA levels in a Chinese population of BPH patients. The study found that PSA levels reduced by approximately 40% during finasteride therapy, and that when baseline PSA was greater than 4ng/ml, decreasing PSA level by approximately 50%. The second study examined whether prostate cancer patients undergoing treatment with dutasteride showed a tendency to have elevated PSA values. The study found that some patients showed clinical indications of hidden significant cancer despite a non-elevated PSA level, and that diagnosis with MRI or other imaging, as well as subsequent follow-up, should be considered for patients with a relatively high PSA even if dutasteride treatment has lowered PSA level. The third study compared the efficacy of silodosin and tamsulosin in patients suffering from acute urinary retention caused by BPH. The study found that both drugs were effective in increasing the likelihood of a successful trial without catheter following AUR.